Ikaika Therapeutics Inc.

Oak Park, IL

UEI
GQ4FG4U8L9W4
CAGE
228J1
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
  • Woman Owned Business
  • Woman Owned Small Business
Entity structure
Corporate Entity (Not Tax Exempt)
NAICS codes registered in SAM.gov
SAM.gov registration date
Physical address
611 Fair Oaks Ave, Oak Park, IL 60302, USA
Website
ikaikatherapeutics.com
Employees
1-10
Estimated annual revenue
$0-$1M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Biotechnology
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Recent federal awards

Ikaika Therapeutics Inc.'s 2 most recent federal contract and grant awards, newest first. Amounts are dollars obligated.
Award Agency Obligated Awarded
Preclinical development of anti-LTPB4 monoclonal antibodies to treat neuromuscular diseases - abstract neuromuscular… Grant · R44AR087317 National Insititue of Arthritis and Musculoskeletal and Skin Diseases $995,938
Project title: a phase 1 clinical trial evaluating the safety and anticancer activity of PQ203 in patients with breast… Grant · HT9425261E363 Defense Health Agency $1,249,647

Quick answers

What is Ikaika Therapeutics Inc.'s UEI?

Ikaika Therapeutics Inc.'s Unique Entity ID (UEI) in SAM.gov is GQ4FG4U8L9W4.

What is Ikaika Therapeutics Inc.'s CAGE code?

Ikaika Therapeutics Inc.'s CAGE code is 228J1.

What is Ikaika Therapeutics Inc.'s primary NAICS code?

Ikaika Therapeutics Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).

Where is Ikaika Therapeutics Inc. located?

Ikaika Therapeutics Inc.'s physical address in SAM.gov is 611 Fair Oaks Ave, Oak Park, IL 60302, USA.

Is Ikaika Therapeutics Inc. registered in SAM.gov?

Yes. Ikaika Therapeutics Inc.'s SAM.gov registration is active through June 25, 2027.

What is Ikaika Therapeutics Inc.'s most recent federal award?

Ikaika Therapeutics Inc.'s most recent federal grant award is Preclinical development of anti-LTPB4 monoclonal antibodies to treat neuromuscular diseases - abstract neuromuscular… (R44AR087317), from National Insititue of Arthritis and Musculoskeletal and Skin Diseases, on September 1, 2026.

On GovTribe

See Ikaika Therapeutics Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login